A Phase II Study of LBH589B in Adult Patients with Refractory Cutaneous T-Cell Lymphoma and Prior HDAC Inhibitor Therapy.
Latest Information Update: 03 Oct 2021
At a glance
- Drugs Panobinostat (Primary)
- Indications Cutaneous T-cell lymphoma; Mycosis fungoides; Sezary syndrome
- Focus Therapeutic Use
- 25 May 2021 Status changed from completed to discontinued(due to low prevalence of study population and slow accrual)
- 27 Apr 2012 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
- 23 Feb 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.